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Abstract 
 
Aim: To examine how patient perspectives and person-centred care values have 
been represented in documents on medicines optimisation policy in England. 
 
Background: There has been growing support in England for a policy of 
medicines optimisation as a response to the rise of problematic polypharmacy. 
Conceptually, medicines optimisation differs from the medicines management 
model of prescribing in being based around the patient rather than processes 
and systems. This critical examination of current official and independent policy 
documents questions how central the patient is in them and whether relevant 
evidence has been utilised in their development.  
 
Methods: A documentary analysis of reports on medicines optimisation 
published by the Royal Pharmaceutical Society (RPS), The King’s Fund, and 
National Institute for Health and Social Care Excellence (NICE) since 2013. The 
analysis draws on a non-systematic review of research on patient experiences of 
using medicines. 
 
Findings: The reports varied in their inclusion of patient perspectives and 
person-centred care values, and in the extent to which they drew on evidence 
from research on patients’ experiences of polypharmacy and medicines use. In 
the RPS report, medicines optimisation is represented as being a ‘step change’ 
from medicines management, in contrast to the other documents which suggest 
that it is facilitated by the systems and processes that comprise the latter model. 
Only The King’s Fund report considered evidence from qualitative studies of 
people’s use of medicines. However, these studies are not without their 
limitations. 
 
We suggest five ways in which researchers could improve this evidence base and 
so inform the development of future policy: by facilitating reviews of existing 
research; conducting studies of patient experiences of polypharmacy and 
multimorbidity; evaluating medicines optimisation interventions; making better 
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use of relevant theories, concepts and tools; and improving patient and public 
involvement in research and in guideline development.  
 
[295/300 word limit] 
 
Key words 
Guidelines; medicines optimisation; multimorbidity; patient-centred prescribing; 
person-centred care; polypharmacy 
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Introduction 
There have been some important developments in policy on medicines 
optimisation in England in recent years. In 2013, the Royal Pharmaceutical 
Society (Picton and Wright 2013) and The King’s Fund (Duerden, Avery and 
Payne 2013) separately published independent reports describing the rise of 
polypharmacy and promoting strategies for optimising the growing use of 
multiple medicines by individual patients. These reports were followed by the 
production of official guidelines on medicines optimisation by the National 
Institute for Health and Social Care Excellence (NICE 2015). In this paper we 
critically examine the ways in which patient perspectives have been 
incorporated in these influential independent reports and official guidelines. We 
also highlight gaps in research on people’s experiences of polypharmacy that 
need to be addressed in order to inform the future development of more 
inherently person-centred medicines optimisation policy and practice in the 
National Health Service (NHS). 
 
Methods 
We carried out a non-systematic review of the English-language research 
literature relating to patient experiences of polypharmacy. The review was wide-
ranging, covering relevant empirical, theoretical and methodological work, as 
well as UK policy documents on the topic,  without date restrictions. It was 
carried out between February and July 2015 as a precursor to a research 
proposal being developed to design, implement and evaluate a complex 
intervention based in primary care in the National Health Service (NHS) for 
optimising medicines use by patients who take multiple medications ([REF 
REMOVED]). 
 
We did not attempt a systematic review of the literature on patients’ experiences 
of polypharmacy with or without multimorbidity at this stage in our preparatory 
work because we were aware that such evidence was hard to locate (and a sub-
project in itself). For example, studies on this topic tend to use different 
terminology; relevant findings are also often reported in the context of wider 
studies of patients’ experiences of chronic illness using qualitative or mixed 
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methods. For these reasons relevant evidence is not easily found using 
mechanical search procedures. Instead, we did three things. We started with the 
literature that we knew on patient experiences of using medicines and followed 
up relevant references. Then we began compiling a list of terms that we might 
use to search the literature more systematically. Finally, we used some of these 
terms to search Google, PubMed and other targeted sources (such as specific 
journals) for relevant papers, while continuing to compile our vocabulary of 
terms for a future more comprehensive review. 
 
This process was very revealing, highlighting major issues with the array of 
terms used (and variously defined) in research on polypharmacy and medicines 
usage. A list of the terms we have compiled to date is [available from the first 
author / in the online methodological appendix] {TO BE ADVISED}. For the 
purposes of this paper, we refer to a few of the 34 studies we identified to 
illustrate key findings and gaps in this literature. We hope to carry out a more 
thorough and complete narrative review of this literature using the terms we 
have identified as part of our ongoing work. 
 
In our initial reading of the policy documents, we noted some variation in how 
central patients were in them, as well as how limited reference was to relevant 
research on patient experiences of using medicines. We carried out the present 
documentary analysis to examine in more depth how patient perspectives had 
been incorporated and to consider how future research might better inform 
policy on medicines optimisation.  
 
In the paper, we focus on the current policy advice produced for healthcare 
professionals in England. This is because, as we describe below, it differs from 
that of Scotland in promoting person-centred care values and in positing 
medicines optimisation as a way of managing the rise of polypharmacy and some 
of the problems associated with it. Our discussion of the implications of our 
findings is, however, relevant to researchers and policymakers across the UK and 
in other countries where the rise of polypharmacy is a matter of concern.  
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Overview of medicines optimisation guidelines in England 
‘Medicines optimisation’ is a relatively new model of prescribing that is currently 
being promoted by the National Institute for Health and Care Excellence (NICE) 
and by independent organisations to succeed the established ‘medicines 
management’ approach in England. In this section we examine how the new 
model is conceptualised and differentiated from the old one in major policy 
reviews and guidelines as being more centred around patients and less 
concerned with processes and systems of prescribing. 
 
In 2013, the Royal Pharmaceutical Society (RPS) published Medicines 
optimisation: helping patients to make the most of medicines (Picton and Wright 
2013). It states that:  
‘Medicines optimisation is about ensuring that the right patients get the 
right choice of medicine, at the right time. By focusing on patients and 
their experiences, the goal is to help patients to: improve their outcomes; 
take their medicines correctly; avoid taking unnecessary medicines; 
reduce wastage of medicines; and improve medicines safety. Ultimately 
medicines optimisation can help encourage patients to take ownership of 
their treatment’ (Picton and Wright 2013: introduction). 
Developed with input from healthcare professionals, patients and the 
pharmaceutical industry, the report provides guidance on good practice for 
healthcare professionals in England, based around four key principles: (1) aim to 
understand the patient’s experience; (2) evidence-based choice of medicines; (3) 
ensure medicines use is as safe as possible; and (4) make medicines optimisation 
part of routine practice. The outcomes that these principles are intended to 
influence are shown in Table 1. 
 
The RPS principles have been agreed by NHS England and used to inform the 
ongoing development of its Medicines Optimisation Prototype Dashboard 
(www.england.nhs.uk/ourwork/pe/mo-dash) and wider Medicines Optimisation 
strategy. They have also been agreed by The Association of the British 
Pharmaceutical Industry, The Royal College of Nursing, The Royal College of 
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General Practitioners and The Academy of Medical Royal Colleges (Keele Centre 
for Medicines Optimisation 2015: 6). 
 
Table 1: RPS four guiding principles of medicines optimisation and their 
intended outcomes 
 
In the same year, The King’s Fund, an independent ‘think tank’, issued 
Polypharmacy and medicine optimisation: making it safe and sound (Duerden, 
Avery and Payne 2013). The authors examine the nature and extent of the 
problem of polypharmacy in the UK, and consider the implications for policy and 
practice. A key distinction is made between ‘appropriate’ and ‘problematic’ 
polypharmacy. The former is achieved when: ‘prescribing for an individual for 
complex conditions or for multiple conditions in circumstances where medicines 
use has been optimised and where the medicines are prescribed according to 
best evidence’ whereas the latter occurs when ‘multiple medications are 
prescribed inappropriately, or where the intended benefit of the medication is 
not realised’ (Duerden, Avery and Payne 2013: 1). 
 
According to the report, the ‘overall intent for the combination of medicines 
prescribed should be to maintain good quality of life, improve longevity and 
minimise harm from drugs’ (Duerden, Avery and Payne 2013: 1). So medicines 
optimisation is intended to support the achievement of appropriate 
polypharmacy for these various needs and minimise the occurrence of 
problematic polypharmacy. However, the latter occurs for a number of reasons, 
such as when the treatments are not evidence-based, or the risk of harm is likely 
to outweigh benefit, or the combination of drugs is hazardous because of 
interactions between them, or the demands of medicine-taking are unacceptable 
to patients, or the demands make it difficult to achieve clinically useful 
medication adherence, or when medicines are prescribed to treat the side effects 
of other medicines even though other solutions are available to reduce the 
number of medicines prescribed (Duerden, Avery and Payne 2013: 1). 
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The authors go on to propose some solutions to problematic forms of 
polypharmacy based on processes associated with medicines management and 
the newer notion of ‘medicines optimisation’. They claim that the latter model, 
with its wider focus on how medicines are or are not used by people, is 
fundamental to addressing problematic polypharmacy. As they put it: ‘Medicines 
optimisation, or robust medicines management, helps to ensure more 
appropriate polypharmacy so that the various trade-offs of harm, benefit and 
patient acceptability and choice have been considered and an explicit decision on 
the drug to use has been made with the patient’ (Duerden, Avery and Payne 
2013: 2). Throughout the report, they stress the need for clinicians to involve 
patients in decisions on drug use.  
 
In March 2015, following a public consultation from 2013-2014 (NICE 2013, 
2014), NICE published the guideline NG5: Medicines optimisation: the safe and 
effective use of medicines to enable the best possible outcomes (NICE 2015a).  The 
NICE guideline adopts The King’s Fund’s definitions of appropriate and 
problematic polypharmacy and describes medicines optimisation as ‘a person-
centred approach to the safe and effective use of medicines’ (NICE 2015a: 5). It 
notes that this approach replaces the previous focus on systems, processes and 
behaviours that was characteristic of medicines management, although the latter 
is still viewed as ‘an important enabler of medicines optimisation’ (NICE 2015a: 
8). The eight topic areas covered by the NICE recommendations for practice, and 
the four for research, are listed in Table 2. 
 
Table 2: NICE recommendations for practice and research on medicines 
optimisation: topic areas 
 
Elsewhere in the UK, NHS Scotland’s Polypharmacy Guidance, originally 
published in 2012, was recently updated in 2015 (Scottish Government Model of 
Care Polypharmacy Working Group 2012, 2015; Wilson, Mair, Dreischulte and 
Wilson 2015). Although published over a similar timescale, these guidelines 
differ in some important respects from those for NHS England. First, they define 
the positive and negative forms of polypharmacy slightly differently, preferring 
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the terms ‘appropriate’ and ‘inappropriate’ polypharmacy, and describing the 
particular conditions when each is present  (Scottish Government Model of Care 
Polypharmacy Working Group 2015: 5; Wilson, Mair, Dreischulte and Wilson 
2015: 109). Secondly, they do not promote medicines optimisation as a model 
for dealing with inappropriate forms of polypharmacy. Instead, the Scottish 
report outlines a ‘7-steps’ Medication Review Process to inform patients’ and 
clinicians’ decision-making about medicines. Finally, this process is not 
described as a person-centred (or patient-centred) approach as such. 
 
In the rest of the paper we focus on how, unlike Scotland, policy in England has 
promoted a shift to the more person-centred medicines optimisation model as a 
strategic response to the rise of polypharmacy. Although the RPS, The King’s 
Fund and NICE guideline all support this strategy, as we show below, their 
reports vary in how integral patient perspectives and person-centred care values 
are to them, and also in the extent to which they draw on evidence from existing 
research on people’s experiences of medicines use in general, and polypharmacy 
in particular. 
 
Centrality of patient perspectives and person-centred care in the 
guidelines 
In the RPS report, medicines optimisation is represented as a ‘step change’ from 
the medicines management approach, focussing on patients and the outcomes 
that matter to them, rather than on professionals and the systems and processes 
that shape how medicines are used (Picton and Wright 2013: introduction). 
While the RPS report emphasises the divergence between the two models, both 
The King’s Fund report and NICE guideline highlight the convergence: they tend 
to represent medicines optimisation as a broad approach that is facilitated by 
processes and systems of medicines management. 
 
This difference in perception of the two models is reflected in the extent to which 
the respective guidelines are formulated around patients. In the RPS guidelines, 
the need to understand patient experiences is relatively strongly represented, 
forming one of its four fundamental principles of medicines optimisation. Many 
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of the RPS recommendations are also written from the patient’s viewpoint (see 
Table 1). 
 
In The King’s Fund report, the importance of determining patient perspectives is 
a running theme, although here it is represented more as a matter for clinicians 
to address on an individual basis rather than, say, as a guiding principle of care 
or a systemic issue, and there are no references to practical information on how 
to go about this. There is just a short section - less than a page in the 56-page 
report – summarising what is known about patient experiences of 
polypharmacy. 
 
Similarly, the 47-page NICE guideline has a one-page section describing ‘person-
centred care’ (which it treats as equivalent to ‘patient-centred care’) that is 
somewhat separate from, and not integrated with, the rest of the report. 
Moreover, the actual recommendations are mainly concerned with processes 
and systems for making safe and cost-effective decisions with less space given to 
ways of facilitating the identification and achievement of person-centred goals. 
This is also reflected in the companion information NICE produced for the public 
(NICE 2015b). 
 
Despite their common support for medicine optimisation, a model that is 
conceptually distinguished from medicines management by its greater focus on 
patient perspectives, only The King’s Fund report engages with real examples of 
the sorts of issues patients have experienced, albeit briefly. In a short section on 
‘Polypharmacy and the patient experience’ the authors describe some of the 
evidence about people’s strategic use of medicines and difficulties coping with 
the demands of their drug regimens (Duerden, Avery and Payne 2013: 32). They 
also discuss a key issue that is glossed over in the other reports – that patients 
and professionals do not always agree about medicines usage - and suggest ways 
of dealing with this. As they point out: ‘Patients may not want to take multiple 
medicines, or prefer one treatment over another. Advice should be given on 
which interventions may be most likely to minimise side effects, reduce 
symptoms and improve outcomes. Regimens may need to be tailored to fit with 
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patient preferences and “compromise” may be required’ (Duerden, Avery and 
Payne 2013: 1-2). 
 
Expanding on these ideas, the authors go on to add that: 
 ‘Compromises may often need to be reached between the view of the 
prescriber in delivering interventions intended to improve outcome, and 
the choice made by the patient, based on the demands of the medication 
regimen. The alternative is the potentially wasteful process of prescribing 
where the patient does not take the medicines appropriately, or does not 
take them at all, but the prescriber unwittingly continues to supply 
prescriptions. Various estimates of long-term drug use indicate that as 
many as 40 per cent of people on long-term prescriptions do not take 
them as intended [ref]’ (Duerden, Avery and Payne 2013:32). 
Closely related to this theme, which again only The King’s Fund report mentions, 
is the notion of the ‘demands’ of the drug regimen and the ‘pill burden’ that 
patients often find unacceptable, which are two of the manifold reasons why 
patients may sometimes choose not to use medicines (Duerden, Avery and Payne 
2013: 1). 
 
Utilisation of research in the guidelines 
The three reports were each informed by associated reviews of the literature. 
However, there was noticeable variation in the extent to which they covered 
qualitative studies of people’s use of medicines. For example, the RPS report 
draws on an undated review of evidence (RPS, undated) that it published 
separately online at www.rpharms.com/medicines-safety/medicines-
optimisation.asp. Most of the 16 references in the report itself refer to research 
on prescribing practices. The consultation document (NICE 2014) that the NICE 
guideline was developed from summarises evidence from systematic reviews, 
randomised controlled trials and observational studies but not qualitative 
studies of people’s experiences of using medicines. Only The King’s Fund report 
considers some of the evidence from qualitative studies of people’s experiences 
of using medicines in its more comprehensive review. 
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The under-utilisation of qualitative research on people’s experiences of using 
medicines is disappointing given that there is a large international literature on 
the topic and on patients’ self-management of chronic conditions, which often 
includes a focus on medicines usage. This work has examined, among other 
things, the reasons why some people do not always take their medicines as 
prescribed (e.g. Britten 2007), the disruptive effects of being ill and fitting 
complex care regimens into everyday life, and the various strategies that people 
have adopted to minimise these effects (Demain et al 2015). However, while 
information on these and other aspects of medicines usage is (and was) already 
available in the literature and could have been better utilised in the guidelines, 
this evidence base is not without limitations. 
 
Much of what we know about people’s use of medicines is based on evidence 
from studies of patients with single conditions, such as diabetes or asthma. Only 
a small proportion of the existing literature focuses on people who take multiple 
medications for multiple conditions. This is important because, while people may 
take two or more medicines for a single condition, those taking multiple 
medicines for multiple conditions, and those prescribing for them, face some 
additional issues. While it is not our intention to fully review the literature on 
people’s experiences of polypharmacy and multimorbidity here, we highlight 
below some of the complex issues that have been identified by studies carried 
out in the UK to date, which are relevant to policy and guidelines on medicines 
optimisation but not so far addressed by them. 
 
In an early study of the views of people with multi-morbidity on their complex 
drug regimens, Townsend et al (2003, 2006) found tensions in their experiences 
of ‘regular’ versus ‘flexible’ regimens for different drugs. They also found that 
people preferred to minimise their use of prescribed medicines and maximise 
their use of alternative ways of managing their conditions. Another study of 
people with type 2 diabetes and cardiovascular diseases found that they believed 
healthcare professionals were more likely to overprescribe for those with 
comorbid conditions, and that more people prioritized their medicines 
prescribed for their diabetes than for their cardiovascular disease (Stack et al 
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2008). Lindsay (2009) found that people with multiple chronic conditions often 
prioritized one main condition because it was unpredictable, or it was not 
controlled through tablets, or it tended to set off other problems.  
 
Some studies have also begun to document the strategies that people have 
developed to deal with the issues of using multiple medications. For example, a 
qualitative longitudinal study of people’s experiences of multimorbidity, which 
examined people’s shifting priorities over time, found that the prescription of 
medicines from different sources and with various instructions led to some 
confusion but also to the development of pragmatic routines enabling people to 
take control (Morris et al 2011). The authors further observed that: ‘Medication 
management emerged as an anchor or point around which multiple condition 
management could be changed (or abandoned) and represented a point whereby 
a person could either take or abandon control’ (Morris et al 2011: 158). Another 
study of patients who were regularly prescribed four or more medicines for 
chronic conditions found that while some did adapt to their long-term medicines 
use others did so at a cost to their quality of life (Krska et al 2013). 
 
We believe that the lack of research on these and other issues experienced by 
people taking multiple medicines for single or multiple conditions in the UK has 
limited the size and quality of the evidence-base available to potential users. As a 
result, policymakers have lacked relevant evidence to draw upon in preparing 
guidelines on polypharmacy, medicines optimisation and multimorbidity; 
clinicians have lacked meaningful and practical information on how to practice 
optimal prescribing for people with complex or multiple conditions; and patients 
have lacked insights from other patients with first-hand experience about how 
they themselves have developed strategies for self-optimising medications, and 
whether these have been successful or not from their point of view. In the last 
part of the paper we consider some of the ways in which researchers might work 
to improve the evidence base to inform the future production of person-centred 
guidelines on medicines optimisation. 
 
Implications for research 
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Below we suggest five ways in which researchers could help policymakers to 
both make better use of available knowledge on the topic and provide them with 
more evidence about patient experiences of polypharmacy, to inform the future 
development of guidelines on medicines optimisation and ensure that they are 
truly person-centred. 
 
1. Facilitate reviews of research 
One possible reason why the current policy reviews and guidelines make partial 
and limited use of the available research on medicines use is because of the 
amorphous nature of the literature. The literature on patient experiences of 
using multiple medicines is difficult to identify and review because of a lack of 
consistency and clarity in the terminology that is used. There is, for example, no 
commonly accepted definition of the number of medicines involved in 
polypharmacy. In a review of polypharmacy terminology, Bushardt et al (2008: 
386) found that six or more drugs was the most commonly used number. In a 
study of polypharmacy among people with stroke and other morbidities, 
Gallacher et al (2014) observed that five or ten tend to be the most commonly 
used thresholds. Other numbers have also been used to indicate progressive 
levels of polypharmacy. Definitions may be limited to prescription drugs or 
include over the counter drugs as well. 
 
Similarly, while there is general acceptance that the individualisation of drug 
treatments is a good thing, there is no common understanding of what this 
means. As Denford et al (2014) have shown, the terms ‘personalised’ and 
‘individualised’ care have been variously and sometimes vaguely defined in 
published studies. As previously noted, the terms ‘patient-centred’ and ‘person-
centred’ care are sometimes used interchangeably (as in the NICE guideline) or 
the latter can be used to refer to a philosophy of care that is distinct from that of 
the former (e.g. Ekman, Swedberg, Taft et al 2011; Rasmussen, Jørgensen and 
Leyshon 2014). Given the proliferation of terms in this field of research, it is 
important that researchers carefully select and clearly define the terms used in 
studies, and differentiate them from alternatives where necessary, to help 
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facilitate the identification and review of relevant work by users of research 
knowledge. 
 
2. Improve the evidence base on patient experiences of polypharmacy and 
multimorbidity 
As we have noted, relatively little is known about patient experiences of 
polypharmacy, particularly those with multimorbidity. There is a particular need 
for more research on the following topics: 
• patient experiences of polypharmacy, especially those taking multiple 
medicines for multiple chronic conditions, including the disruptiveness 
and burden of their drug regimens, and the making and balancing of 
different priorities;  
• patients’ and prescribers’ understanding of and attitudes to medicines 
optimisation, including their views on the nature and acceptability of 
compromises;  
• patient and prescriber perspectives on the acceptability, safety and 
effectiveness of particular interventions designed to optimise medicines 
use; 
• patient and prescriber perspectives on the barriers and facilitators to the 
optimisation of medicines prescribed by different practitioners across 
primary and secondary care settings. 
These topics will in some cases require a longitudinal approach, for example, 
examining how patients’ priorities and use of medicines shift over time, what 
influences this, and how adaptations to drug regimens can be made in response. 
They also require modes of analysis that bring out the ways in which the design 
and operation of systems of care are reflected and embodied in individual 
patient’s experiences. This includes sensitivity to the language used by patients 
and carers to describe what they regard as good quality care that meets their 
needs and priorities, which is not always the same as that used by services or in 
policy. An article on patients’ and carers’ experiences of obtaining repeat 
prescriptions provides an example of this approach (Wilson, Kataria and 
McNeilly 2013). 
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3. Improve the evidence base on medicine optimisation interventions 
While the policy documents support a move to medicines optimisation in 
England, they contain little information and practical guidance for healthcare 
professionals and patients on how to work together to achieve this in practice. 
Skinner (2015) has also revealed a lack of clinical protocols for polypharmacy 
that are specific to primary care, although she acknowledges the difficulties of 
providing guidelines for professionals treating individual patients with multiple 
conditions, each of whom have ‘unique’ health priorities (Skinner 2015: 4-5). 
 
In the proposal that we are developing on the back of this work, we are planning 
to design and evaluate a generalist approach to prescribing that can be tailored 
to individuals and their shifting circumstances and priorities ([REF REMOVED]). 
However, this is just one possible study of one approach and others are required 
to investigate the nature and challenges, and benefits and costs, of interventions 
for optimising medicines in different contexts. A recent study in Ireland of how 
general practitioners make compromises when prescribing for patients with 
multimorbidity is a helpful contribution to knowledge in this regard (Sinnott, Mc 
Hugh, Boyce and Bradley 2015). 
 
4. Better use of existing and emerging theories, concepts and tools 
There are a number of theoretical frameworks that could be used to inform 
future conceptual and empirical research on polypharmacy and medicines 
optimisation. These include debates around the notions of ‘patient-centred’ and 
‘person-centred’ care and how these fit with ideas about medicines optimisation 
and evidence-based medicine. They also include theories such as generalism and 
how this might provide the basis for reshaping practice around people rather 
than their diseases (Reeve and Bancroft 2014). There are also concepts such as 
‘burden of treatment’ (May, Eton, Boehmer et al 2014) and ‘minimally disruptive 
medicine’ that are salient and informing the development of tools for measuring 
the impact of interventions in terms that are more relevant to patients (Lepping, 
Montori and Gionfriddo 2015). 
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These theoretical approaches, in their different ways, provide possible 
alternatives to existing conceptual models of prescribing, which have been 
largely influenced by ideas about patients’ adherence (and previously 
compliance) to medication regimens. For a long time these ideas have failed to 
fundamentally engage with patients’ perspectives on how they routinely use 
medicines to better enable them to live their lives and so a new approach is 
needed. 
 
5. Improved patient and public involvement in research and in the development of 
guidelines 
One way of improving the centrality of patients in guidelines purporting to 
promote patient- or person-centred care is to increase their meaningful 
involvement in research and in the development of guidelines and clinical 
protocols. It is encouraging to see that NHS England has so far carried out two 
patient engagement workshops in the course of developing their Medicines 
Optimisation strategy (www.england.nhs.uk/ourwork/pe/mo-dash). Krahn and 
Naglie (2008) have argued that patients’ perspectives, experiences and choices 
should be considered at every stage of the development and implementation of 
clinical practice guidelines. They suggest five ways of doing this: finding 
preference-related evidence; integrating preference-related evidence into 
recommendations; using guidelines in individual decision making; including 
patients in the guideline development process; and evaluating guidelines with 
preferences in mind (Krahn and Naglie 2008: 437). 
 
More recently, Montori and colleagues (2013), working out of the Knowledge 
and Research (KER) Unit at the Mayo Clinic in the United States, have similarly 
called for the incorporation of patient preferences into practice guidelines. They 
suggest that guideline panels should include frontline patients and clinicians; 
consult with clinical and methodological experts and seek testimony from 
individuals who are experts in patient preferences, patients, and caregivers’, as 
well as commission relevant reports; and rely on patient input to ‘drive 
consideration of the full range of outcomes patients experience and consider 
critical in deciding what to do’ (Montori, Brito and Murad 2013: 2504). They also 
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suggest that panels should refrain from making ‘strong’ recommendations when 
‘the best course of action heavily depends on the patient’s context, goals, values, 
and preferences’; instead they advise panels to make ‘conditional 
recommendations’ that reflect this scenario and presents options in a way that 
facilitates shared decision making (Montori, Brito and Murad 2013: 2504).  
 
In what we regard as a refreshing dose of realism, they conclude by arguing that: 
‘Panels should become much more comfortable with ambiguity, both in 
the tradeoffs involved and in the recommendations given, and explicitly 
report how patient preferences and context were considered in 
formulating the panels’ recommendations. Clinicians need guidance and 
clear guidance helps and supports efficient practices. Yet, panels must be 
wise in recognizing when this expediency is appropriate for patient care 
and when it hinders patient-centred care. Clinicians should remember 
that taking care of patients is supposed to be difficult. Although guidelines 
may simplify this task, when patient preferences and context matter, 
guidelines must not replace clinicians’ compassionate and mindful 
engagement of the patient in making decisions together. This is the 
optimal practice of evidence-based medicine’ (Montori, Brito and Murad 
2013: 2504). 
 
We would reiterate that patients, too, need to be involved as members of panels 
and, more generally, in discussions around ‘ambiguity’ and ‘compromises’ in 
prescribing and debates about the ethics and values which inform decision-
making in prescribing. 
 
Conclusion 
In this paper we have drawn attention to the different ways in which patient 
perspectives and person-centred care values have been represented in official 
and influential independent policy documents on medicines optimisation in 
England. Whereas understanding patient perspectives is a fundamental principle 
of the RPS guidelines, the more recent NICE guideline focuses mainly on the safe 
and effective prescribing of medicines, and less on the identification and 
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achievement of personal goals, which are also important to patients. We have 
argued that this partly reflects a lack of utilisation of existing qualitative research 
on patient experiences of polypharmacy, especially where linked to 
multimorbidity, as well as a lack of basic research specifically on this topic. We 
have suggested some topics that we believe are priorities for further research, 
and highlighted ways in which patients can be more fully involved in the process 
of developing guidelines. We hope that researchers, funders of research, and 
policymakers will use our suggestions to help improve the construction of 
guidelines on medicines optimisation that are meant to enable patients to get the 
most from their medicines. 
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